JPH10313822A - Intestinal bacterial flora improver and composition containing the same - Google Patents

Intestinal bacterial flora improver and composition containing the same

Info

Publication number
JPH10313822A
JPH10313822A JP9145981A JP14598197A JPH10313822A JP H10313822 A JPH10313822 A JP H10313822A JP 9145981 A JP9145981 A JP 9145981A JP 14598197 A JP14598197 A JP 14598197A JP H10313822 A JPH10313822 A JP H10313822A
Authority
JP
Japan
Prior art keywords
primeverose
weight
parts
pts
intestinal flora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9145981A
Other languages
Japanese (ja)
Inventor
Masamichi Ishigami
政道 石神
Noriaki Oka
憲明 岡
Masanori Okada
正紀 岡田
Kanzo Sakata
完三 坂田
Yasuichi Usui
泰市 碓氷
Shuji Watanabe
修治 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Chemical Industries Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP9145981A priority Critical patent/JPH10313822A/en
Publication of JPH10313822A publication Critical patent/JPH10313822A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain the subject improver composed of primeverose for improving intestinal bacterial flora by accelerating growth of the so-called benign bacteria, e.g. Bifidobacterium. SOLUTION: This improver is composed of primeverose, showing functions of accelerating growth of Bifidobacterium and improving intestinal bacterial flora. A tablet type health food can be produced by, e.g. tabletting a mixture of 20 pts.wt. of primeverose, 40 pts.wt. of lactose, 1 pt.wt of calcium lactate, 1 pt.wt. of zinc stearate, 10 pts.wt. of freeze-dried Bifidobacterium, 8 pts.wt. of hydroxypropylmethyl cellulose and 20 pts.wt. of cellulose.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、腸内細菌叢を改善
するのに好適な食品組成物に関する。
TECHNICAL FIELD The present invention relates to a food composition suitable for improving intestinal flora.

【0002】[0002]

【従来の技術】プリメベロースはグルコピラノースの6
位とキシロースの1位とがエーテル結合により結合した
2糖類であって、自然界に於いてはプリメベロースの1
位にテルペン等のアグリコンが結合した配糖体が存在す
ることが知られている。プリメベロースそれ自体につい
ては、その存在が知られているものの、そのものが所有
している性質、作用については多くは知られていない。
取り分け、この物質が腸内菌叢の改善に有益であること
は全く知られていない。又、このものは通常食されてい
る食品素材中には含まれていないため、これを食品素材
として用いることも、これを含有する食品を食すること
も全く知られていないし、行われていない。
BACKGROUND OF THE INVENTION Primeverose is a glucopyranose 6
Is a disaccharide in which the 1-position of xylose and the 1-position of xylose are linked by an ether bond.
It is known that there exists a glycoside in which an aglycone such as terpene is bonded at the position. Primeverose itself is known for its existence, but much is unknown about the properties and actions it possesses.
In particular, it is completely unknown that this substance is beneficial for improving the intestinal flora. In addition, since this is not contained in food materials that are usually eaten, it is not known or used to use it as a food material, nor to eat foods containing it. .

【0003】他方、腸内細菌叢の細菌組成は下痢症、便
秘症、感染症へ大きな影響を与え、この細菌叢の細菌組
成を変えること、例えば、ビフィズス菌などの好ましい
細菌類を増殖させることは、前記疾患の予防及び症状改
善に大変有益であることが既に臨床研究から明らかにさ
れている。又、この様な腸内細菌叢を改善する手段とし
て、N−アセチルグルコサミンやパンテチン類、ある種
のペプチド類、核酸関連物質、胃酸で消化されないラク
チュロース等の糖類等を投与し、ビフィズス菌を増殖促
進させる方法が既に知られている。しかしながら、これ
らの物質には作用の強さや異臭等による使用量の制限等
必ずしも満足のいく効果を発現しうる状況にはなかっ
た。即ち、新たな腸内細菌叢を改善する手段の登場が待
たれているのが現状であった。
[0003] On the other hand, the bacterial composition of the intestinal flora greatly affects diarrhea, constipation and infectious diseases, and alters the bacterial composition of the flora, for example, to grow favorable bacteria such as bifidobacteria. Has already been shown from clinical studies to be very beneficial for the prevention and amelioration of symptoms. As means for improving such intestinal flora, N-acetylglucosamine, pantethines, certain peptides, nucleic acid-related substances, saccharides such as lactulose that cannot be digested by stomach acid, and the like are administered to grow Bifidobacteria. Methods for promoting are already known. However, these substances were not in a state where a satisfactory effect such as limitation of the amount of use due to the strength of action or off-flavor or the like could be necessarily exerted. That is, at present, the appearance of a new means for improving the intestinal flora has been awaited.

【0004】[0004]

【発明が解決しようとする課題】本発明はこの様な状況
下為されたものであり、腸内細菌叢を改善する手段を提
供することを課題とする。
SUMMARY OF THE INVENTION The present invention has been made under such circumstances, and it is an object of the present invention to provide means for improving the intestinal flora.

【0005】[0005]

【課題の解決手段】本発明者らはかかる状況に鑑みて、
腸内細菌叢を改善する手段を求めて鋭意研究を重ねた結
果、プリメベロースにその様な作用があることを見いだ
した。更にプリメベロースを含有する食品組成物を摂取
することにより腸内細菌叢において、ビフィズス菌等の
いわゆる善玉菌が増殖促進され、腸内細菌叢が改善され
ることを見いだし、発明を完成させるに至った。以下、
本発明の実施の形態を中心に更に詳細に本発明について
説明を加える。
In view of such a situation, the present inventors
As a result of intensive studies in search of means for improving the intestinal flora, it was found that primeverose has such an effect. Furthermore, by ingesting a food composition containing primeverose, in the intestinal flora, so-called good bacteria such as bifidobacteria are promoted to grow, and it has been found that the intestinal flora is improved, thereby completing the invention. . Less than,
The present invention will be described in more detail mainly on the embodiments of the present invention.

【0006】[0006]

【発明の実施の形態】BEST MODE FOR CARRYING OUT THE INVENTION

(1)本発明の腸内細菌叢改善剤 本発明の腸内細菌叢改善剤はプリメベロースからなる。
プリメベロースはグルコピラノースの6位とキシロース
の1位とがエーテル結合により結合した2糖類であっ
て、自然界に於いてはプリメベロースの1位にテルペン
等のアグリコンが結合した配糖体が存在することが知ら
れている。プリメベロースそれ自体については、その存
在が知られているものの、そのものが所有している性
質、作用については多くは知られていない。このものは
化学合成では、例えば、アセチルグルコピラノースとα
−アセトブロモキシロースとを硝酸銀などを触媒にして
反応させれば得ることができる。又、酵素合成であれ
ば、D−グルコースとキシロビオースとをペクチナーゼ
等の酵素の存在下縮合させれば得ることができる。これ
らの製造法の内好ましいものは立体選択性に優れる酵素
合成法である。以下、酵素合成法の例を示す。
(1) Intestinal flora improving agent of the present invention The intestinal flora improving agent of the present invention comprises primeverose.
Primeverose is a disaccharide in which the 6th position of glucopyranose and the 1st position of xylose are linked by an ether bond, and in nature, there is a glycoside in which an aglycone such as terpene is linked to the 1st position of primeverose. Are known. Primeverose itself is known for its existence, but much is unknown about the properties and actions it possesses. In chemical synthesis, for example, acetylglucopyranose and α
-It can be obtained by reacting acetobromoxylose with silver nitrate or the like as a catalyst. In the case of enzyme synthesis, it can be obtained by condensing D-glucose and xylobiose in the presence of an enzyme such as pectinase. Among these production methods, preferred is an enzyme synthesis method having excellent stereoselectivity. Hereinafter, examples of the enzyme synthesis method will be described.

【0007】(製造例)100mMクエン酸燐酸緩衝液
(pH4.0)中、キシロビオースとグルコースとをモ
ル比1:2でペクチナーゼの存在下(1.5U/ml)
40℃で24時間反応させた後、5分間加熱して反応を
停止させた。反応液を水で平衡化した活性炭−セライト
を担体としたカラムクロマトグラフィーで精製し(溶出
溶媒;水:エタノール100:0→70:30)、しか
る後エタノールから再結晶してキシロビオース42mg
あたり6.35%の収率でプリメベロースを得た。
(Production Example) Xylobiose and glucose in a 100 mM citrate phosphate buffer (pH 4.0) at a molar ratio of 1: 2 in the presence of pectinase (1.5 U / ml)
After reacting at 40 ° C. for 24 hours, the reaction was stopped by heating for 5 minutes. The reaction solution was purified by column chromatography using activated carbon-celite as a carrier equilibrated with water (elution solvent; water: ethanol 100: 0 → 70: 30), and then recrystallized from ethanol to obtain 42 mg of xylobiose.
Permeverose was obtained in a yield of 6.35%.

【0008】かくして得られたプリメベロースは後記実
施例に示すように、腸内細菌叢に於いて、ビフィズス菌
等のいわゆる善玉細菌数を増やし、腸内細菌叢を整え、
腸内細菌叢の乱れに起因する下痢症、便秘症、感染症等
の予防・治療に優れた作用を発揮する。これは、プリメ
ベロースが胃酸などの消化液に対して安定であり、その
大部分は大腸に到達し、ビフィズス菌等善玉菌の栄養培
地となり、酢酸や乳酸などの産生を促進し腸内のpHを
低下させて自発性感染症等の原因となる細菌や腐敗細菌
の生育を抑制し、これら有害細菌が産生するアンモニ
ア、インドール、クレゾール等の発生を抑制することが
できる。
[0008] The thus obtained premeverose increases the number of so-called good bacteria such as bifidobacteria in the intestinal flora and regulates the intestinal flora, as shown in Examples below.
It exerts an excellent effect on the prevention and treatment of diarrhea, constipation, infectious diseases, etc. caused by disturbance of the intestinal flora. This is because primeverose is stable against digestive juices such as stomach acid, and most of it reaches the large intestine, becomes a nutrient medium for beneficial bacteria such as bifidobacteria, promotes the production of acetic acid and lactic acid, etc. It is possible to suppress the growth of bacteria and spoilage bacteria that cause spontaneous infectious diseases and the like by lowering them, and suppress the generation of ammonia, indole, cresol, etc. produced by these harmful bacteria.

【0009】(2)本発明の食品組成物 本発明の食品組成物は、上記プリメベロースからなる腸
内細菌叢改善剤を含有することを特徴とする。本発明の
食品組成物に於けるプリメベロースの好ましい含有量
は、食品の種類により多少変動することもあるが、0.
01〜20重量%であり、より好ましくは0.05〜1
5重量%であり、更に好ましくは0.1〜10重量%で
ある。本発明の食品組成物としては、食品形態のもので
あれば特段の限定を受けずに適用することが可能であ
り、例えば、キャンディー、チョコレート、羊羹、ウイ
ロウ、ケーキ、クッキー等の菓子類、麺類、パン、ピザ
等の主食類、ヨーグルト、チーズ等の乳製品類、ソーセ
ージ、ハム等の肉類加工品、カマボコ、竹輪、はんぺん
等の魚肉加工品、カレー、ホワイトシチュー、ビーフシ
チュー等のレトルト或いは缶詰食品等が例示できる。本
発明の食品組成物では、必須成分であるプリメベロース
以外に、これらの食品組成物で使用されている任意成分
を含有することができる。任意成分としては、穀物、肉
類、野菜類、魚類等の主要食材はもとより、矯味矯臭
剤、保存料、アミノ酸類、甘味料、香辛料、保存料、抗
酸化剤、鮮度保持剤、発色剤、着色剤、酸味料、苦味
料、乳化剤、増粘剤、安定剤、分散剤等が挙げられる。
更に、腸内細菌叢を改善させる作用のある物質も含有さ
せることが可能である。この様な物質としては、N−ア
セチルグルコサミンやパンテチン類、ある種のペプチド
類、核酸関連物質、胃酸で消化されないラクチュロース
等の糖類等が例示できる。更にビフィズス菌やブルガリ
ヤヨーグルト菌等の菌体も配合することが可能である。
又、プリメベロースにはカルシウム、マグネシウム、
鉄、マンガン、亜鉛、銅、カリウム、燐等の微量元素を
吸収促進する作用もあるので本発明の食品組成物はこれ
らの欠乏症を予防・改善する作用も有する。更に、プリ
メベロースはう蝕作用もないので、虫歯などの心配も少
ない。又、消化されにくいため糞便量も増大するので、
細菌叢の改善と相まって便秘を改善・予防できる。人間
のみならず家畜や家禽の食品としても好適に使用でき
る。
(2) Food composition of the present invention The food composition of the present invention is characterized by containing an intestinal flora improving agent comprising the above-mentioned primeverose. The preferred content of primeverose in the food composition of the present invention may slightly vary depending on the type of food, but is preferably 0.1%.
0.01 to 20% by weight, more preferably 0.05 to 1% by weight.
It is 5% by weight, more preferably 0.1 to 10% by weight. The food composition of the present invention can be applied without any particular limitation as long as it is in the form of food, for example, sweets such as candy, chocolate, yokan, willow, cake, cookies, noodles Staple foods such as bread, pizza, etc., dairy products such as yogurt and cheese, processed meat products such as sausages and hams, processed fish products such as kamaboko, bamboo rings, and starch, retorts or canned curries, white stews, beef stews, etc. Foods and the like can be exemplified. The food composition of the present invention may contain optional components used in these food compositions, in addition to premeverose, which is an essential component. Optional ingredients include main ingredients such as grains, meats, vegetables, and fish, as well as flavoring agents, preservatives, amino acids, sweeteners, spices, preservatives, antioxidants, freshness preservatives, coloring agents, and coloring. Agents, sour agents, bitter agents, emulsifiers, thickeners, stabilizers, dispersants and the like.
Further, it is possible to contain a substance having an effect of improving the intestinal flora. Examples of such substances include N-acetylglucosamine and pantethines, certain peptides, nucleic acid-related substances, and sugars such as lactulose that are not digested by gastric acid. Bacteria such as Bifidobacterium and Bulgarian yogurt can also be added.
In addition, calcium, magnesium,
Since the food composition of the present invention also has an action of promoting the absorption of trace elements such as iron, manganese, zinc, copper, potassium and phosphorus, the food composition of the present invention also has an action of preventing and improving these deficiencies. Furthermore, since premeverose has no caries effect, there is little worry about caries. Also, because it is difficult to digest, the amount of feces also increases,
Constipation can be improved and prevented in combination with the improvement of the bacterial flora. It can be suitably used not only for humans but also for livestock and poultry.

【0010】[0010]

【実施例】以下に実施例を挙げて本発明について更に詳
細に説明するが、本発明がこれら実施例にのみ限定を受
けないことは言うまでもない。
The present invention will be described in more detail with reference to the following examples, but it goes without saying that the present invention is not limited to these examples.

【0011】<実施例1>プリメベロースの消化性につ
いて、岡田らの方法(日本栄養・食料学会誌、第43
巻、第1号、23頁)に従ってインビトロで試験した。
比較例としてマルトース、トレハロース、イソマルトー
スを用いた。結果を分解率(全糖に対するグルコースの
生成割合)で表1に示す。この結果よりプリメベロース
は各種消化液に安定であって、大腸まで到達することが
判る。又、消化されにくいため低カロリー糖質と言うこ
とができる。即ち、本発明の食品組成物は低カロリー食
品としても好適であることが判る。
<Example 1> The digestibility of primeverose was determined by the method of Okada et al. (Journal of Japan Society of Nutrition and Food Science, No. 43).
Vol. 1, No. 23, in vitro).
Maltose, trehalose, and isomaltose were used as comparative examples. The results are shown in Table 1 in terms of the decomposition rate (producing ratio of glucose to total sugars). From these results, it can be seen that primeverose is stable in various digestive fluids and reaches the large intestine. In addition, since it is difficult to digest, it can be called a low calorie sugar. That is, it turns out that the food composition of the present invention is also suitable as a low-calorie food.

【0012】[0012]

【表1】 [Table 1]

【0013】<実施例2>プリメベロースのビフィズス
菌等の善玉腸内細菌及び悪玉腸内細菌に対する、資化性
を調べた。即ち、光岡知足著、叢文社刊、「腸内菌の世
界(嫌気性菌の分離と同定)」、325頁(1984
年)の記載に従って、PYF培地及び糖を0.5w/v
%添加した加糖PYF培地で37℃で96時間培養し、
培養液を5倍希釈しその濁度から腸内細菌の生育度を求
めた。比較例としては、グルコース、トレハロース、イ
ソマルトースを用いた。濁度は、0.1未満を−、0.
1以上1.5未満を±、1.5以上0.2未満を+、
0.2以上0.3未満を++、0.3以上を+++と判
定した。結果を表2に示す。この表より、プリメベロー
スはビフィドバクテリウム(ビフィズス菌)やラクトバ
チラス(乳酸菌)等の善玉腸内菌にのみ選択的に資化性
を有しており、これらの腸内に於ける増殖を促進するこ
とが判る。即ち、実施例1の結果と考えあわせると、プ
リメベロースを経口投与することにより、腸内細菌叢を
改善することができる事が判る。
Example 2 The assimilation of primeverose with respect to good intestinal bacteria such as bifidobacteria and bad intestinal bacteria was examined. That is, Tomohiko Mitsuoka, published by Sobunbunsha, “World of Intestinal Bacteria (Separation and Identification of Anaerobic Bacteria)”, p. 325 (1984)
Year), the PYF medium and sugar were added at 0.5 w / v.
Cultured at 37 ° C. for 96 hours in a sweetened PYF medium containing
The culture solution was diluted 5-fold, and the growth of intestinal bacteria was determined from the turbidity. As comparative examples, glucose, trehalose, and isomaltose were used. Turbidity is less than 0.1, minus 0.1.
1 to less than 1.5 ±, 1.5 to less than 0.2 +,
0.2 or more and less than 0.3 were determined as ++, and 0.3 or more was determined as +++. Table 2 shows the results. From this table, it can be seen that Primeverose selectively assimilates only to good intestinal bacteria such as Bifidobacterium (Bifidobacterium) and Lactobacillus (Lactobacillus) and promotes their growth in the intestine. You can see that. That is, in consideration of the results of Example 1, it can be understood that oral administration of primeverose can improve intestinal bacterial flora.

【0014】[0014]

【表2】 [Table 2]

【0015】<実施例3>予め、濃縮飼料で飼育したマ
ウスを用いて、グルコース、イソマルトース、トレハロ
ース、プリメベロースの投与による糞量の変化を調べ
た。即ち、固形飼料を粉砕したもの50重量部と大豆蛋
白10重量部とラード10重量部を混練り成形した飼料
で4週間飼育したICRマウス(雄性、35〜40g)
1群10匹を、固形飼料を粉砕したもの70重量部と糖
類30重量部を混練り成形した飼料で3日間代謝ケージ
中で飼育し、3日間の総糞量を測定した。対照群は固形
飼料のみを与えた。結果を対照群に対する糞量の増加率
[(投与群の糞量−対照群の糞量)/対照群の糞量×1
00]として、表3に示す。この表より、プリメベロー
ス投与群は糞量が著しく増加しており、プリメベロース
が便秘などの改善に有効であることが判る。
Example 3 Changes in the amount of feces caused by administration of glucose, isomaltose, trehalose, and primeverose were examined using mice that had been bred in advance with a concentrated feed. That is, ICR mice (male, 35 to 40 g) reared for 4 weeks on a feed obtained by kneading and mixing 50 parts by weight of a solid feed, 10 parts by weight of soybean protein and 10 parts by weight of lard
Ten animals per group were bred in a metabolic cage for 3 days on a feed obtained by kneading and forming 70 parts by weight of a crushed solid feed and 30 parts by weight of a saccharide, and the total amount of feces for 3 days was measured. The control group received only chow. The result was expressed as the rate of increase in fecal volume relative to the control group [(fecal volume of administration group-fecal volume of control group) / fecal volume of control group x 1
00] is shown in Table 3. From this table, it can be seen that the amount of feces in the premeverose-administered group is significantly increased, and that the premeverose is effective in improving constipation and the like.

【0016】[0016]

【表3】 [Table 3]

【0017】<実施例4>次に示す処方で錠剤状の健康
食品を作成した。即ち、粉体成分を良く混合し、打錠機
にて打錠して200mgの錠剤を得た。便秘に悩む人5
名にこの錠剤を朝、昼、晩各2錠づつ、1カ月飲んでも
らったところ、全員便秘が改善し、内3名は毎日1回規
則正しく便通があるようになった。 プリメベロース 20 重量部 乳糖 40 重量部 乳酸カルシウム 1 重量部 ステアリン酸亜鉛 1 重量部 ビフィズス菌凍乾物 10 重量部 ヒドロキシプロピルメチルセルロース 8 重量部 セルロース 20 重量部
Example 4 A tablet-shaped health food was prepared according to the following formulation. That is, the powder components were mixed well and tableted with a tableting machine to obtain a tablet of 200 mg. People suffering from constipation 5
When they took this tablet two times each in the morning, afternoon, and evening for one month, constipation improved, and three of them began to have regular bowel movements once a day. Primeverose 20 parts by weight Lactose 40 parts by weight Calcium lactate 1 part by weight Zinc stearate 1 part by weight Bifidobacterium lyophilizate 10 parts by weight Hydroxypropyl methylcellulose 8 parts by weight Cellulose 20 parts by weight

【0018】<実施例5>下記に示す処方に従って、ジ
ュースを作成した。即ち、処方成分を良く混合し、滅菌
した後、瓶に無菌充填し、密閉してジュースを得た。 バレンシアオレンジ果汁 50 重量部 ニンジンジュース 30 重量部 プリメベロース 10 重量部 ビタミンC 0.1重量部 ビタミンB6塩酸塩 0.1重量部 イソマルトース 9.8重量部
Example 5 A juice was prepared according to the following recipe. That is, the prescription components were mixed well, sterilized, filled aseptically into a bottle, and sealed to obtain a juice. Valencia orange juice 50 parts by weight Carrot juice 30 parts by weight Primeverose 10 parts by weight Vitamin C 0.1 part by weight Vitamin B6 hydrochloride 0.1 part by weight Isomaltose 9.8 parts by weight

【0019】<実施例6>下記に示す処方に従って、キ
ャンディーを作成した。即ち、処方成分を加熱溶解し、
型に流し込み冷却固化させて、型から外しキャンディー
を得た。 水飴 40 重量部 プリメベロース 5 重量部 クエン酸 0.1重量部 白糖 54.9重量部
Example 6 A candy was prepared according to the following recipe. That is, the formulation components are heated and dissolved,
The mixture was poured into a mold, cooled and solidified, and removed from the mold to obtain a candy. Starch syrup 40 parts by weight primeverose 5 parts by weight citric acid 0.1 parts by weight sucrose 54.9 parts by weight

【0020】<実施例7>下記に示すに従って、パンを
作成した。即ち、処方成分を良く混練りし、40℃で4
0分間一次発酵し、ガス抜きした後成形し、40℃で3
5分二次発酵し、200℃で30分オーブンで焼いて、
室温に冷却してパンを得た。 強力粉 500 重量部 食塩 10 重量部 ドライイースト 10 重量部 プリメベロース 15 重量部 バター 30 重量部 牛乳 210 重量部
<Example 7> Bread was prepared in the following manner. That is, the ingredients are kneaded well at 40 ° C.
Primary fermentation for 0 minutes, molding after degassing,
Secondary fermentation for 5 minutes, bake in oven at 200 ° C for 30 minutes,
Cooling to room temperature gave a bread. Strong flour 500 parts by weight Salt 10 parts by weight Dry yeast 10 parts by weight Primeverose 15 parts by weight Butter 30 parts by weight Milk 210 parts by weight

【0021】<実施例8>下記に示す処方に従ってカマ
ボコを得た。即ち、処方成分を良く混練りし、板に塗り
付け成形し、蒸気で蒸し上げカマボコを得た。 スケトウダラの擂り身 89.9重量部 プリメベロース 10 重量部 ビタミンC 0.1重量部
Example 8 Kamaboko was obtained according to the following formulation. That is, the ingredients were kneaded well, coated and molded on a plate, and steamed with steam to obtain Kamaboko. Alaska pollack ground meat 89.9 parts by weight Primeverose 10 parts by weight Vitamin C 0.1 part by weight

【0022】[0022]

【発明の効果】本発明によれば、腸内細菌叢を改善する
手段を提供することができる。
According to the present invention, means for improving the intestinal flora can be provided.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 坂田 完三 静岡県静岡市大谷836 静岡大学農学部内 (72)発明者 碓氷 泰市 静岡県静岡市大谷836 静岡大学農学部内 (72)発明者 渡辺 修治 静岡県静岡市大谷836 静岡大学農学部内 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Kanzo Sakata 836 Otani, Shizuoka City, Shizuoka Prefecture Inside the Faculty of Agriculture, Shizuoka University (72) Inventor Yasushi Usui 836 Otani, Shizuoka City, Shizuoka Prefecture Inside the Faculty of Agriculture, Shizuoka University (72) Inventor Shuji Watanabe 836 Otani, Shizuoka City, Shizuoka Prefecture Shizuoka University Faculty of Agriculture

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 プリメベロースからなる腸内細菌叢改善
剤。
1. An intestinal flora improving agent comprising primeverose.
【請求項2】 腸内細菌叢改善がビフィズス菌増殖促進
作用である、請求項1に記載の腸内細菌叢改善剤。
2. The intestinal flora-improving agent according to claim 1, wherein the improvement of the intestinal flora is an action of promoting the growth of bifidobacteria.
【請求項3】 請求項1又は2に記載の腸内細菌叢改善
剤を含有する食品組成物。
3. A food composition comprising the intestinal flora improving agent according to claim 1 or 2.
【請求項4】 プリメベロースを含有する食品組成物。4. A food composition containing primeverose. 【請求項5】 腸内細菌叢改善作用を有することを特徴
とする請求項4に記載の食品組成物。
5. The food composition according to claim 4, which has an intestinal flora improving effect.
JP9145981A 1997-05-20 1997-05-20 Intestinal bacterial flora improver and composition containing the same Pending JPH10313822A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9145981A JPH10313822A (en) 1997-05-20 1997-05-20 Intestinal bacterial flora improver and composition containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9145981A JPH10313822A (en) 1997-05-20 1997-05-20 Intestinal bacterial flora improver and composition containing the same

Publications (1)

Publication Number Publication Date
JPH10313822A true JPH10313822A (en) 1998-12-02

Family

ID=15397441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9145981A Pending JPH10313822A (en) 1997-05-20 1997-05-20 Intestinal bacterial flora improver and composition containing the same

Country Status (1)

Country Link
JP (1) JPH10313822A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515552A (en) * 1999-12-03 2003-05-07 サイメディカ リミテッド Pharmaceutical product that can be taken by mouth and method for producing the same
JP2017537156A (en) * 2014-11-28 2017-12-14 アナジェニックス アイピー リミテッドAnagenix Ip Limited Gold kiwi fruit composition and method for its preparation and use

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515552A (en) * 1999-12-03 2003-05-07 サイメディカ リミテッド Pharmaceutical product that can be taken by mouth and method for producing the same
JP2017537156A (en) * 2014-11-28 2017-12-14 アナジェニックス アイピー リミテッドAnagenix Ip Limited Gold kiwi fruit composition and method for its preparation and use
US10512663B2 (en) 2014-11-28 2019-12-24 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor
US11090348B2 (en) 2014-11-28 2021-08-17 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor
US11642386B2 (en) 2014-11-28 2023-05-09 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor

Similar Documents

Publication Publication Date Title
EP2156751B1 (en) Novel sweetener having sugar-like taste and production method and use of the same
EP0667107B1 (en) Bifidobacterium growth promoter
US7994155B2 (en) Accelerator for mineral absorption and use thereof
JP2779963B2 (en) Bifidobacterium growth promoter
JP5270144B2 (en) Use of maltobionic acid, its salt or maltobiono delta lactone-containing composition
US8940715B2 (en) Lipid-regulating agent and use thereof
US8461130B2 (en) Food containing glycogen and use thereof
KR0161531B1 (en) Process for preparing lactosucrose high-content powder and use of said powder
JP3381010B2 (en) Fermented product containing propolis extract, production method and use thereof
JP5875603B2 (en) Bifidobacterium growth promoter
JP2006502103A (en) Condensed palatinose and method for producing the same
TW200410702A (en) Agent for inhibiting rise in blood glucose level, agent for inhibiting body fat accumulation and edible material
JP3557711B2 (en) Foods and manufacturing methods effective for improving lipid metabolism
WO2006132223A1 (en) Anti-hypertensive composition
JPH1084909A (en) Intestinal butyric acid concentration increase accelerating agent
JPH0937711A (en) Health food
JP5586713B2 (en) Mineral solubilizer
JPH10313822A (en) Intestinal bacterial flora improver and composition containing the same
JP3681193B2 (en) α-Isomaltosyl α-isomaltoside, production method thereof and use
JP2014210718A (en) Intestinal barrier function-improving agent
JP5695098B2 (en) Lipid metabolism improver
JP3678452B2 (en) Bifidobacteria growth promoter, its production method and use
JP5628355B2 (en) Mineral absorption promoter and easily absorbable calcium agent
JP7401156B1 (en) Agents for preventing and/or treating inflammation in the uterus, fallopian tubes and ovaries
JPH10298082A (en) Osteo enhancer